Analgesic potential of TRPV1 antagonists - PubMed (original) (raw)
. 2009 Aug 1;78(3):211-6.
doi: 10.1016/j.bcp.2009.02.014. Epub 2009 Mar 5.
Affiliations
- PMID: 19481638
- DOI: 10.1016/j.bcp.2009.02.014
Analgesic potential of TRPV1 antagonists
Philip R Kym et al. Biochem Pharmacol. 2009.
Abstract
The discovery of TRPV1 antagonists as a new class of analgesic agents for the treatment of chronic pathological pain has been pursued aggressively across the pharmaceutical industry. This effort has led to the identification of several TRPV1 antagonists that have entered clinical trials, including ABT-102 (Abbott), SB-705498 (GSK), AMG-517 (Amgen), MK2295 (Merck/Neurogen), and GRC-6211 (Lilly/Glenmark). Using the published structures for ABT-102, SB-705498, AMG-517, and lead compounds representing six additional TRPV1 antagonist chemotypes, a pharmacophore model that describes the common structural features found in potent TRPV1 antagonists was established. The TRPV1 antagonist pharmacophore fits within the pore region of a TRPV1 receptor homology model, with critical hydrogen bond interactions proposed between the TRPV1 antagonist pharmacophore and Tyr 667 on helix six. In spite of the putative common binding site for all TRPV1 antagonists included in this particular TRPV1 pharmacophore, these ligands have demonstrated that they can still offer distinct pharmacological profiles, likely due to differences in their pharmacokinetic profiles. This is highlighted by differences in temperature elevation observed when comparing the clinical candidates ABT-102 and AMG-517.
Similar articles
- TRPV1 antagonists: clinical setbacks and prospects for future development.
Kort ME, Kym PR. Kort ME, et al. Prog Med Chem. 2012;51:57-70. doi: 10.1016/B978-0-12-396493-9.00002-9. Prog Med Chem. 2012. PMID: 22520471 Review. No abstract available. - Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
Honore P, Chandran P, Hernandez G, Gauvin DM, Mikusa JP, Zhong C, Joshi SK, Ghilardi JR, Sevcik MA, Fryer RM, Segreti JA, Banfor PN, Marsh K, Neelands T, Bayburt E, Daanen JF, Gomtsyan A, Lee CH, Kort ME, Reilly RM, Surowy CS, Kym PR, Mantyh PW, Sullivan JP, Jarvis MF, Faltynek CR. Honore P, et al. Pain. 2009 Mar;142(1-2):27-35. doi: 10.1016/j.pain.2008.11.004. Epub 2009 Jan 9. Pain. 2009. PMID: 19135797 - Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
Gomtsyan A, Bayburt EK, Schmidt RG, Surowy CS, Honore P, Marsh KC, Hannick SM, McDonald HA, Wetter JM, Sullivan JP, Jarvis MF, Faltynek CR, Lee CH. Gomtsyan A, et al. J Med Chem. 2008 Feb 14;51(3):392-5. doi: 10.1021/jm701007g. Epub 2008 Jan 10. J Med Chem. 2008. PMID: 18183945 - Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
Gunthorpe MJ, Hannan SL, Smart D, Jerman JC, Arpino S, Smith GD, Brough S, Wright J, Egerton J, Lappin SC, Holland VA, Winborn K, Thompson M, Rami HK, Randall A, Davis JB. Gunthorpe MJ, et al. J Pharmacol Exp Ther. 2007 Jun;321(3):1183-92. doi: 10.1124/jpet.106.116657. Epub 2007 Mar 28. J Pharmacol Exp Ther. 2007. PMID: 17392405 - TRPing the switch on pain: an introduction to the chemistry and biology of capsaicin and TRPV1.
Conway SJ. Conway SJ. Chem Soc Rev. 2008 Aug;37(8):1530-45. doi: 10.1039/b610226n. Epub 2008 Jun 20. Chem Soc Rev. 2008. PMID: 18648679 Review.
Cited by
- Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels.
De Petrocellis L, Schiano Moriello A, Fontana G, Sacchetti A, Passarella D, Appendino G, Di Marzo V. De Petrocellis L, et al. Br J Pharmacol. 2014 May;171(10):2608-20. doi: 10.1111/bph.12320. Br J Pharmacol. 2014. PMID: 23902373 Free PMC article. - Novel scaffolds for modulation of TRPV1 identified with pharmacophore modeling and virtual screening.
Goldmann D, Pakfeifer P, Hering S, Ecker GF. Goldmann D, et al. Future Med Chem. 2015;7(3):243-56. doi: 10.4155/fmc.14.168. Future Med Chem. 2015. PMID: 25826358 Free PMC article. - TRPV1 antagonist with high analgesic efficacy: 2-Thio pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides.
Ha TH, Ryu H, Kim SE, Kim HS, Ann J, Tran PT, Hoang VH, Son K, Cui M, Choi S, Blumberg PM, Frank R, Bahrenberg G, Schiene K, Christoph T, Frormann S, Lee J. Ha TH, et al. Bioorg Med Chem. 2013 Nov 1;21(21):6657-64. doi: 10.1016/j.bmc.2013.08.015. Epub 2013 Aug 13. Bioorg Med Chem. 2013. PMID: 24035514 Free PMC article. - α-Methylated simplified resiniferatoxin (sRTX) thiourea analogues as potent and stereospecific TRPV1 antagonists.
Kim HS, Jin MK, Kang SU, Lim JO, Tran PT, Hoang VH, Ann J, Ha TH, Pearce LV, Pavlyukovets VA, Blumberg PM, Lee J. Kim HS, et al. Bioorg Med Chem Lett. 2014 Jun 15;24(12):2685-8. doi: 10.1016/j.bmcl.2014.04.054. Epub 2014 Apr 23. Bioorg Med Chem Lett. 2014. PMID: 24794110 Free PMC article. - Pyridine C-region analogs of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists.
Ryu H, Seo S, Lee JY, Ha TH, Lee S, Jung A, Ann J, Kim SE, Yoon S, Hong M, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Schiene K, Stockhausen H, Christoph T, Frormann S, Lee J. Ryu H, et al. Eur J Med Chem. 2015 Mar 26;93:101-8. doi: 10.1016/j.ejmech.2015.02.001. Epub 2015 Feb 2. Eur J Med Chem. 2015. PMID: 25659771 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources